Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADTX NASDAQ:BPTSY NASDAQ:JAGX NYSE:PTN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADTXAditxt$1.03-5.5%$1.34$1.02▼$21,400.00$2.31M1.5857,112 shs217,306 shsBPTSYBiophytis$1.81$1.57$1.33▼$7.48$634K0.811,745 shsN/AJAGXJaguar Animal Health$1.98-2.9%$3.01$1.93▼$35.25$2.08M0.4395,835 shs41,194 shsPTNPalatin Technologies$0.09-44.6%$0.09$0.09▼$2.48$2.45M0.942.28 million shs14.57 million shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADTXAditxt-5.50%-13.45%-17.60%-53.81%-99.99%BPTSYBiophytis0.00%0.00%+24.48%-6.96%-68.55%JAGXJaguar Animal Health-2.94%-11.61%-22.96%-84.75%-93.56%PTNPalatin Technologies0.00%0.00%0.00%-56.82%+9,409,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADTXAditxtN/AN/AN/AN/AN/AN/AN/AN/ABPTSYBiophytisN/AN/AN/AN/AN/AN/AN/AN/AJAGXJaguar Animal Health1.6825 of 5 stars3.53.00.00.00.60.00.6PTNPalatin TechnologiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADTXAditxt 0.00N/AN/AN/ABPTSYBiophytis 0.00N/AN/AN/AJAGXJaguar Animal Health 3.00Buy$60.002,930.30% UpsidePTNPalatin Technologies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest BPTSY, ADTX, JAGX, and PTN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/19/2025JAGXJaguar Animal HealthFirst BerlinSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$60.00(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADTXAditxt$130K16.80N/AN/A($1.52) per share-0.68BPTSYBiophytisN/AN/AN/AN/A($16.18) per shareN/AJAGXJaguar Animal Health$11.69M0.17N/AN/A$12.29 per share0.16PTNPalatin Technologies$350K6.99N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADTXAditxt-$34.45MN/A0.00∞N/A-46,082.47%-389.10%-84.71%8/18/2025 (Estimated)BPTSYBiophytis-$18.43MN/A0.00∞N/AN/AN/AN/AN/AJAGXJaguar Animal Health-$38.49MN/A0.00N/AN/A-343.92%-432.91%-71.25%8/12/2025 (Estimated)PTNPalatin TechnologiesN/A-$1.55N/A∞N/AN/AN/AN/AN/ALatest BPTSY, ADTX, JAGX, and PTN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/12/2025Q2 2025JAGXJaguar Animal Health-$7.13N/AN/AN/A$3.27 millionN/A5/15/2025Q1 2025ADTXAditxt-$26,400.00-$8.12+$26,391.88-$8.12$0.43 million$0.00 million5/15/2025Q1 2025JAGXJaguar Animal Health-$18.50-$16.70+$1.80-$16.70$3.29 million$3.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADTXAditxtN/AN/AN/AN/AN/ABPTSYBiophytisN/AN/AN/AN/AN/AJAGXJaguar Animal HealthN/AN/AN/AN/AN/APTNPalatin TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADTXAditxtN/A0.080.08BPTSYBiophytisN/A0.41N/AJAGXJaguar Animal Health22.201.080.70PTNPalatin TechnologiesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADTXAditxt15.54%BPTSYBiophytis0.05%JAGXJaguar Animal Health12.04%PTNPalatin Technologies11.50%Insider OwnershipCompanyInsider OwnershipADTXAditxt0.01%BPTSYBiophytis3.70%JAGXJaguar Animal Health4.55%PTNPalatin Technologies7.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADTXAditxt602.12 million2.12 millionNo DataBPTSYBiophytis30351,000338,000N/AJAGXJaguar Animal Health501.02 million972,000No DataPTNPalatin Technologies3026.01 millionN/AN/ABPTSY, ADTX, JAGX, and PTN HeadlinesRecent News About These CompaniesPalatin Technologies, Inc. (PTN) Q3 2025 Earnings Call TranscriptMay 15, 2025 | seekingalpha.comPalatin Technologies Inc (PTNT) Q3 2025 Earnings Call Highlights: Strategic Advances Amid ...May 15, 2025 | gurufocus.comQ3 2025 Palatin Technologies Inc Earnings Call TranscriptMay 14, 2025 | gurufocus.comPalatin Expects $11.5 Mln Offering To Aid NYSE Compliance And Fuel Obesity Drug DevelopmentMay 9, 2025 | nasdaq.comPalatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025May 9, 2025 | prnewswire.comPalatin Technologies Announces Encouraging Pre-Clinical Data Of PL9588 For Glaucoma TreatmentMay 7, 2025 | nasdaq.comPalatin Technologies faces delisting from NYSE American due to low stock priceMay 7, 2025 | in.investing.comPalatin Technologies faces delisting from NYSE American due to low stock priceMay 7, 2025 | in.investing.comNYSE American to Commence Delisting Proceedings Against Palatin Technologies, Inc. (PTN)May 7, 2025 | businesswire.comPalatin Expects $11.5 Million Financing to Cure NYSE American Delisting NoticeMay 7, 2025 | prnewswire.comPalatin Technologies Announces Pricing of up to $23 Million Public OfferingMay 7, 2025 | prnewswire.comPalatin Presents Promising Preclinical Data for Melanocortin Agonist PL9588 at ARVO 2025, Highlighting a Dual-Action Glaucoma TherapyMay 5, 2025 | prnewswire.comPL9643 shows promise in dry eye disease treatmentApril 30, 2025 | investing.comPalatin Reports Positive Results From Responder Analyses Of Phase 3 MELODY-1 Study In DEDApril 30, 2025 | nasdaq.comPalatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye DiseaseApril 29, 2025 | prnewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBPTSY, ADTX, JAGX, and PTN Company DescriptionsAditxt NASDAQ:ADTX$1.03 -0.06 (-5.50%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.04 +0.01 (+0.97%) As of 08/1/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Aditxt, Inc., a biotech company, engages in the development and commercialization of technologies that focus on improving the health through monitoring and modulating the immune systems. The company develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its tissues. It also develops ADI-100 for skin grafting, psoriasis, type 1 diabetes, and multiple sclerosis. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.Biophytis NASDAQ:BPTSY$1.80 0.00 (0.00%) As of 08/1/2025Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics focuses on targeting and activating key biological resilience pathways that could protect against and counteract the effects of the multiple biological and environmental stresses including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is Sarconeos (BIO101), an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD), as well as in Phase 2/3 clinical study for the treatment of severe respiratory failure in patients suffering from COVID-19. It also develops Macuneos (BIO201), an orally administered small molecule for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis SA has a collaboration agreement with AFM-Telethon for the development of its Sarconeos (BIO101) for the treatment of DMD. The company was incorporated in 2006 and is headquartered in Paris, France.Jaguar Animal Health NASDAQ:JAGX$1.98 -0.06 (-2.94%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$1.97 -0.01 (-0.51%) As of 08/1/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Jaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. The company's products include Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy; and Canalevia-CA1, a prescription drug product for chemotherapy-induced diarrhea in dogs. It is also developing Crofelemer, an anti-secretory antidiarrheal drug, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, the company is developing NP-300, a second-generation antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea. The company is headquartered in San Francisco, California.Palatin Technologies NYSE:PTN$0.09 -0.08 (-44.65%) As of 05/7/2025Palatin Technologies, Inc., a biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the United States. The company's lead product is Vyleesi, a melanocortin receptor (MCr) agonist for the treatment of premenopausal women with hypoactive sexual desire disorder. It is also developing oral PL8177, a selective MC1r agonist peptide that has completed Phase I clinical trial for the treatment of inflammatory bowel diseases. In addition, the company engages in the development of PL9643, a peptide melanocortin agonist active at multiple MCrs, including MC1r and MC5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. Further, it is developing PL3994, a natriuretic peptide receptor (NPR)-A agonist and synthetic mimetic of the endogenous neuropeptide hormone atrial natriuretic peptide for cardiovascular indications; and PL5028, an NPR-A and NPR-binder to treat cardiovascular and fibrotic diseases, including reducing cardiac hypertrophy and fibrosis. The company was incorporated in 1986 and is based in Cranbury, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/28 - 08/01 Alphabet Gains Momentum as Sentiment on Wall Street Improves Amazon's Earnings: What Comes Next and How to Play It Apple Stock: Big Earnings, Small Move—Time to Buy? Tesla Teams With Samsung—Will Other Chipmakers Follow? Will Hims & Hers Fall Along With Novo Nordisk? UPS's 7.5% Dividend: A Blue-Chip Stock on a Once-in-a-Decade Sale Is PG&E an AI Power Play? Why Options Traders Are Betting Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
